Navigation Links
Inflection Biosciences licenses preclinical oncology programs from the CNIO
Date:6/4/2013

Inflection Biosciences Ltd, a private company focused on the development of targeted small molecule treatments for cancer, today announced that it has entered into a license agreement with the Spanish National Cancer Research Centre (CNIO) for the exclusive, worldwide rights to develop and commercialise several novel kinase inhibitors for the treatment of cancer.

The compounds leverage the CNIO's considerable expertise in drug discovery and comprise a novel pan-PIM kinase inhibitor program and a number of unique multi-targeting kinase inhibitors combining activity on PIM kinase and additional kinases including the phosphoinositide-3 kinase and the mammalian target of rapamycin (PI3K/mTOR) pathway. All molecules have shown good activity in preclinical models, are orally- available with excellent pharmaceutical properties.

Dr María Blasco, Director of CNIO added "It is a great satisfaction for the CNIO to join forces with the experienced team at Inflection Biosciences, allowing us to take full advantage of our ability to innovate cancer treatments."

Dr Michael O'Neill, Co-Founder and Director of Research and Development at Inflection Biosciences commented "Following an extensive global search we are delighted to have secured assets in late preclinical stages of development of this quality and potential and from an organisation recognised internationally for the quality of its cancer research and its drug discovery programs."


'/>"/>

Contact: Press Office
comunicacion@cnio.es
Centro Nacional de Investigaciones Oncologicas (CNIO)
Source:Eurekalert

Page: 1

Related biology news :

1. HUNT Biosciences and SomaLogic collaborate to validate protein biomarkers of cardiovascular risk
2. Amarantus BioSciences to Present at the National Investment Banking Associations (NIBA)122nd Conference in New York City
3. 3-V Biosciences Appoints Douglas I. Buckley, PhD, as Vice President of Biology
4. Althea Technologies & Profectus BioSciences Sign Manufacturing Agreement For Plasmid DNA Production
5. Ben-Gurion U. licenses drug delivery platform for central nervous system diseases to NY biotech firm
6. Collaborative preclinical efficacy studies suggest a new target for drug addiction treatment
7. Preclinical studies use specialized ultrasound to detect presence of cancer
8. Preclinical study shows potential of new technologies to detect response to cancer therapy earlier
9. AACR news: Paragazole excels in preclinical models of triple-negative breast cancer
10. ESMO 2012 Congress: A path for medical oncology innovations
11. TGen-US Oncology data guides treatment of metastatic triple-negative breast cancer patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/5/2018)... ... October 04, 2018 , ... CallTower Inc., ... present at Microsoft Ignite 2018, in Orlando, Florida, when Microsoft made a major ... statement about the new direction of Skype for Business Online, outlining the following ...
(Date:10/5/2018)... (PRWEB) , ... October 04, 2018 , ... High dose ... some of the tests such as cardiac troponin has serious clinical complications. There is ... the exact prevalence is still unknown. , High dose of biotin supplement use ...
(Date:10/3/2018)... ... October 03, 2018 , ... ... development and commercialization of first-in-class stromal cell immunotherapies, announced that ORBCEL-M™, a ... type 2 diabetes and progressive diabetic kidney disease in a four-site, pan-European ...
Breaking Biology News(10 mins):
(Date:10/5/2018)... ... 2018 , ... Shell’s Puget Sound Refinery recently presented the ... high-tech machine that turns plastic into prosthesis. The Million Waves Project collects and ... the usable plastic and turns it into 3D printed prosthetic limbs for children ...
(Date:10/2/2018)... ... October 02, 2018 , ... Finalists for the ... Bio-Energy) AssurEOR product line was chosen for its advancements in the production chemicals ... leading innovations in upstream oil applications that are positively impacting the industry. The ...
(Date:9/28/2018)... ... 2018 , ... GlycoMark®, Inc. has announced a partnership with ... the only FDA-cleared blood test specific to detecting recent hyperglycemia and hyperglycemic excursions ... GlycoMark test to its network of physicians through its sales organization and MD ...
(Date:9/27/2018)... ... September 26, 2018 , ... Medable was named DPharm ... build the first human digitome, a digital representation of human health and disease, ... integration of all data sources. Dr. Michelle Longmire, Co-Founder and CEO of Medable, ...
Breaking Biology Technology: